TAC(TERT activator compound) is an activator of TERT, that upregulates TERT transcription via the MEK/ERK/AP-1 cascade. It enhances telomere synthesis, reduces aging markers, inflammation, and senescence, and preserves brain function, highlighting TERT’s potential in combating aging and related diseases.

TAC(TERT activator compound) is an activator of TERT, that upregulates TERT transcription via the MEK/ERK/AP-1 cascade. It enhances telomere synthesis, reduces aging markers, inflammation, and senescence, and preserves brain function, highlighting TERT’s potential in combating aging and related diseases.

TAC(TERT activator compound) is an activator of TERT, that upregulates TERT transcription via the MEK/ERK/AP-1 cascade. It enhances telomere synthesis, reduces aging markers, inflammation, and senescence, and preserves brain function, highlighting TERT’s potential in combating aging and related diseases.

Pyr3 is a selective and potent inhibitor of transient receptor potential canonical channel 3 (TRPC3). It inhibits TRPC3-mediated Ca2+ influx in a dose-dependent manner with the IC50 value of 0.7 μM. It holds potential for treating TRPC3-related diseases like cardiac hypertrophy.

Pyr3 is a selective and potent inhibitor of transient receptor potential canonical channel 3 (TRPC3). It inhibits TRPC3-mediated Ca2+ influx in a dose-dependent manner with the IC50 value of 0.7 μM. It holds potential for treating TRPC3-related diseases like cardiac hypertrophy.

Pyr3 is a selective and potent inhibitor of transient receptor potential canonical channel 3 (TRPC3). It inhibits TRPC3-mediated Ca2+ influx in a dose-dependent manner with the IC50 value of 0.7 μM. It holds potential for treating TRPC3-related diseases like cardiac hypertrophy.

Pyr3 is a selective and potent inhibitor of transient receptor potential canonical channel 3 (TRPC3). It inhibits TRPC3-mediated Ca2+ influx in a dose-dependent manner with the IC50 value of 0.7 μM. It holds potential for treating TRPC3-related diseases like cardiac hypertrophy.

Tilfrinib (Compound 4f) is a potent and selective inhibitor of the tyrosine-protein kinase Brk/PTK6, with an IC50 of 3.15 nM. It demonstrates significant anti-proliferative activity against breast cancer cell lines MCF7, HS-578T, and BT-549.

Tilfrinib (Compound 4f) is a potent and selective inhibitor of the tyrosine-protein kinase Brk/PTK6, with an IC50 of 3.15 nM. It demonstrates significant anti-proliferative activity against breast cancer cell lines MCF7, HS-578T, and BT-549.

PFI-6 is a selective MLLT1/3 probe that targets the YEATS domain of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3) with IC50 values of 140 nM and 160 nM for MLLT1 and MLLT3, respectively. PFI-6 demonstrates increased affinity and selectivity for MLLT1/3 than other human YEATS domain proteins (YEATS2/4).